Saniona

Saniona EBIT Margin

The EBIT Margin (Operating Margin) of Saniona (SANION.ST) as of Nov 10, 2026 is 63.24 %. In the previous year, EBIT Margin (Operating Margin) was 72.28 % — a change of -12.50% (lower).

EBIT Margin

63.24 %

YoY

-12.50%

Last updated:

EBIT Margin (Operating Margin) of Saniona is 2025 63.24 % . EBIT Margin (Operating Margin) of Saniona was 2024 72.28 % . It decreases by -12.50% lower compared to the previous year.

For Saniona, the operating (EBIT) margin of 63.2% is up versus -3,889.4% a few years ago.

The Saniona EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-98.76 SEK
Jan 1, 2019
-3,909.18 SEK
Jan 1, 2020
-856.04 SEK
Jan 1, 2021
-3,889.41 SEK
Jan 1, 2022
-1,349.39 SEK
Jan 1, 2023
-481.38 SEK
Jan 1, 2024
72.28 SEK
Jan 1, 2025
63.24 SEK
The Saniona EBIT Margin history
YEAREBIT MarginYoY
63.24 %-12.50%
72.28 %-115.01%
-481.38 %-64.33%
-1,349.39 %-65.31%
-3,889.41 %+354.35%
-856.04 %-78.10%
-3,909.18 %+3,858.15%
-98.76 %-64.27%
-276.39 %-4,826.59%
5.85 %-102.84%
-205.98 %+441.71%
-38.02 %+30,409.95%
-0.12 %-55.69%
-0.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Saniona Stock analysis

What does Saniona do? Saniona AB is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for rare diseases. The company was previously known as Saniona AB (until 2014) and NeuroNova AB (until 2012). It was founded in Copenhagen, Denmark, in 2006 and quickly expanded to other countries. In 2013, the company opened an office in Boston, USA, to expand its activities in North America. Saniona AB is listed on the NASDAQ Stockholm and currently has over 60 employees worldwide. The company's business model revolves around discovering and developing drugs for rare diseases that have little to no existing therapies. They use a proprietary technology platform called Ion Channels and G Protein-Coupled Receptors (GPCRs) to identify novel compounds that could meet these urgent medical needs. Saniona AB aims to develop successful medications and sell them either through partnerships or their own marketing activities. The company operates in various areas, including rare diseases, the nervous system (developing drugs for movement disorders and psychiatric disorders), and diabetes and obesity. Saniona AB has several drug candidates in its pipeline targeting different therapeutic applications, with some in various stages of clinical development. One of its key products is Tesomet, a candidate for the treatment of Prader-Willi syndrome and hypothalamic-pituitary hormone disorders, which is currently in Phase 3 of clinical development. Another important candidate is AN788, being investigated in Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis. In conclusion, Saniona AB is an emerging biopharmaceutical company developing innovative drugs for rare diseases. With a specialization in researching rare diseases with significant medical needs and unmet treatment options, the company utilizes a proprietary technology platform to identify new compounds that aim to fulfill these medical needs. With multiple drug candidates in development and a strong partnership strategy, Saniona is well-positioned to maximize the potential of its innovative therapies and benefit patients in need. Saniona is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Saniona stock

EBIT Margin (Operating Margin) of Saniona is 63.24 % in 2025.

EBIT Margin (Operating Margin) of Saniona changed from 72.28 % to 63.24 %, representing a -12.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Saniona since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Saniona with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Saniona

All Key Metrics — Saniona